GM1 Oligosaccharide Efficacy in Parkinson's Disease: Protection Against MPTP
Overview
Authors
Affiliations
Past evidence has shown that the exogenous administration of GM1 ganglioside slowed neuronal death in preclinical models of Parkinson's disease, a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons: however, the physical and chemical properties of GM1 (i.e., amphiphilicity) limited its clinical application, as the crossing of the blood-brain barrier is denied. Recently, we demonstrated that the GM1 oligosaccharide head group (GM1-OS) is the GM1 bioactive portion that, interacting with the TrkA-NGF complex at the membrane surface, promotes the activation of a multivariate network of intracellular events regulating neuronal differentiation, protection, and reparation. Here, we evaluated the GM1-OS neuroprotective potential against the Parkinson's disease-linked neurotoxin MPTP, which destroys dopaminergic neurons by affecting mitochondrial bioenergetics and causing ROS overproduction. In dopaminergic and glutamatergic primary cultures, GM1-OS administration significantly increased neuronal survival, preserved neurite network, and reduced mitochondrial ROS production enhancing the mTOR/Akt/GSK3β pathway. These data highlight the neuroprotective efficacy of GM1-OS in parkinsonian models through the implementation of mitochondrial function and reduction in oxidative stress.
Fazzari M, Lunghi G, Carsana E, Valsecchi M, Spiombi E, Breccia M Int J Mol Sci. 2024; 25(21).
PMID: 39519108 PMC: 11547101. DOI: 10.3390/ijms252111555.
Lunghi G, Di Biase E, Carsana E, Henriques A, Callizot N, Mauri L FEBS Open Bio. 2023; 13(12):2324-2341.
PMID: 37885330 PMC: 10699117. DOI: 10.1002/2211-5463.13727.
Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy.
Castillo Bautista C, Eismann K, Gentzel M, Pelucchi S, Mertens J, Walters H Cells. 2023; 12(18).
PMID: 37759469 PMC: 10527391. DOI: 10.3390/cells12182247.